Rznomics recently announced that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec (RZ-001)', its RNA-editing gene therapy for the treatment of glioma.

The designation follows the positive opinion adopted in September 2026 by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). This marks RZ-001's first regulatory designation in Europe and further strengthens its development foundation across the 2 major markets of the US and Europe.

Orphan Medicinal Product Designation is intended to encourage the development of medicines for rare, serious, or life-threatening conditions. The program offers regulatory and development benefits, including the possibility of market exclusivity following approval, reduced development fees, and support to enhance clinical development efficiency for orphan drugs.

Bomi Kim, Head—Drug Development Center, Rznomics, said, "Following its designation in the United States, RZ-001's orphan designation in Europe provides further positive momentum for its development. Building on this milestone, we will continue to communicate the value of RZ-001 to potential global partners."

RZ-001 has also secured several regulatory designations from the US Food and Drug Administration (FDA), supporting its development prospects and potential partnering value. The FDA has granted Orphan Drug Designation (ODD) and Fast Track designation (FTD) for RZ-001 for treatment of hepatocellular carcinoma (HCC) and glioblastoma (GBM). In addition, RZ-001 received Regenerative Medicine Advanced Therapy (RMAT) designation for HCC in May 2026.

Dr. Seong-Wook Lee, CEO, Rznomics, said, "Glioblastoma has a poor prognosis and remains an area of significant unmet medical need. With the European Commission's orphan designation of RZ-001, we will continue our efforts to develop RZ-001 as a potential new treatment option for patients with difficult-to-treat cancers."

Rznomics aims to advance global partnerships and expand the commercial potential of RZ-001. In addition to HCC and GBM, which are currently under clinical development, the company is pursuing expansion into additional solid tumor indications.